ÅëÇÕ°Ë»ö
ä¿ëÁ¤º¸
ÇìµåÇåÆÃ
ÀÎÀçÁ¤º¸
Ä¿¹Â´ÏƼ
Àαâ°Ë»ö¾î
:
¿µ¾÷
¸¶ÄÉÆÃ
ÀÓ»ó
¿¬±¸
Ç°Áú°ü¸®
ÀλçÃѹ«
»ý»êÁ÷
¾à»ç
ÀÎÇã°¡
°£È£»ç
- À̹ÌÁöºä -
(400x300)
(Oncology)Medical Affairs Director(Doctor)ÀÓ¿ø- ¿Ü±¹°è Á¦¾àȸ»ç
http://www.hrkorea.co.kr
ȸ»ç¸í
HRKorea
´ëÇ¥ÀÚ
¼Á¾¿ø
»ç¿ø¼ö
35¸í
ÀÚº»±Ý
25¾ï¿ø
»ç¾÷³»¿ë
Á÷¾÷Á¤º¸Á¦°ø
¸ðÁýÁ÷Á¾
ÀÇ»ç/¾à»ç/¼öÀÇ»ç/ÇÑÀÇ»ç
£¾
¾à»ç/ÇѾà»ç
,
ÀÇ»ç/¾à»ç/¼öÀÇ»ç/ÇÑÀÇ»ç
£¾
˂ȍ
±Ù¹«Áö¿ª
¼¿ï
ÀüÁö¿ª
´ã´ç¾÷¹«
(Oncology)Medical Affairs Director
¸ðÁýÀοø
¡Û
¸í
±Ù¹«ÇüÅÂ
Á¤±ÔÁ÷
±Þ¿©»çÇ×
ÃßÈÄÇùÀÇ
ÀÚ°Ý¿ä°Ç
¼ºº°
¹«°ü
³ªÀÌ
¹«°ü
ÇзÂ
´ëÇпø(¼®»ç) Á¹¾÷
¡è
°æ·Â
13³â
¡è
»ó¼¼¸ðÁý³»¿ë
(Oncology)Medical Affairs Director(Doctor)ÀÓ¿ø- ¿Ü±¹°è Á¦¾àȸ»ç
1. Job Responsibility
Company CO. Ltd.
Medical Director, Oncology Preferred.
Proactively being involved in clinical development program as a member of ¡®AP Franchise TSG(AP Franchise tumor strategy group)¡¯ and ¡®AP ODL(AP oncology development leadership team)¡¯
: Validate the feasibility and relevance of clinical program into A-P region
: Assure and prioritize clinical program with legitimate timeline from short term to long term perspectives
: Identify A-P stratified tumor types like Gastric ca., HCC, Lung ca. and develop clinical program for these tumor types
: Ensure flawless and seamless execution of study design from regulatory perspectives
: Provide and update Korean treatment patterns, disease profiling and epidemiologic figure to global team
: Update on thought leaders profile for the candidate of Advisory Board, study steering member or PI (primary investigator)
: Persuasive communication with early oncology development team (DMCP) to secure early oncology trial (Phase I)
Closely collaborate with RCO(regional clinical operation) as country medical monitor
: Identify the candidate of investigators and communicate to seek their interest
: Gather deep insight from top experts to ensure study implementation
: Finalize country profiling and the investigators
: Enclosed regular meeting with site manager to monitor operational team
: Engage with RCO(regional clinical operation team) to ensure timely and seamless conduction of clinical trials from study design to final phase
: Resolve issue from SAE or medical affair
: Present as speaker at investigator meeting, site initiation meeting
Plan and direct clinical program as country study director
: Develop study plan to bridge unmet medical needs and data gap
Engage with regulatory affair and medical writer group
: Internally communicate, request and provide the documents for registration with expected manner
: Externally communicate with health authorities to address their concerns and give presentations when official meeting is needed
Other key engagements
- Keep right relationship with TLs (thought leaders) and investigators
- Deep insight gathering from stakeholders
- Study site selection, expansion and country application
- Medical reviewing of promotional document, publishing material and lecture slides
- Audit and inspection on ongoing or completed trials
- Pharmacovigilance activity for safety issue and adverse event
- Delivering knowledge as medical expert to internal or external audience
- People managing for medical advisors
- Value positioning for right product
- Decision maker as KLT (Korea leadership team)
- High level of Spoken & Written English
¼·ùÁ¢¼öE-mail : kschoi@hrkorea.co.kr
´ã´çÄÁ¼³ÅÏÆ®: HR Korea ÃÖ°æ¼÷ºÎ»çÀå
Tel. : 02-3450-1263
Á¢¼ö±â°£
ä¿ë½Ã
Á¦Ãâ¼·ù
À̷¼
Á¢¼ö¹æ¹ý
À̸ÞÀÏ, ¿Â¶óÀÎÁ¢¼ö
À̷¼¾ç½Ä
¿Â¶óÀÎ À̷¼
´ã´çÀÚ
ÃÖ°æ¼÷
¿¬¶ôó
02-3450-1263
À̸ÞÀÏ
kschoi@hrkorea.co.kr
ȨÆäÀÌÁö
http://www.hrkorea.co.kr
ȸ»çÁÖ¼Ò
[137-861] ¼¿ï ¼Ãʱ¸ ¼ÃÊ2µ¿ 1340-6 ³²°ºôµù 11Ãþ
ÃÖÁ¾¼öÁ¤ÀÏ : 2018³â 04¿ù 13ÀÏ
º» Á¤º¸´Â HRKorea¿¡¼ Á¦°øÇÑ ÀÚ·áÀ̸ç, Æĸ¶¸ÞµðÀâ´Â(Àº) ±âÀçµÈ ³»¿ë¿¡ ´ëÇÑ ¿À·ù¿Í Áö¿¬, »ç¿ëÀÚ°¡ À̸¦ ½Å·ÚÇÏ¿© ÃëÇÑ Á¶Ä¡¿¡ ´ëÇÏ¿© Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. º» Á¤º¸´Â Æĸ¶¸ÞµðÀâÀÇ µ¿ÀÇ ¾øÀÌ Àç¹èÆ÷ÇÒ ¼ö ¾ø½À´Ï´Ù.
¼±ÅÃÇϽŠÀ̷¼¿Í ÀÔ·ÂÇϽŠ³»¿ëÀÌ ÇØ´ç¾÷üÀÇ ´ã´çÀÚ¿¡°Ô À̸ÞÀÏ·Î Àü¼ÛµË´Ï´Ù.
Áö¿øÀ̷¼
À̷¼¸¦ ¼±ÅÃÇØÁÖ¼¼¿ä
´ã´çÀÚ¸í
ÃÖ°æ¼÷ (kschoi@hrkorea.co.kr)
º¸³»´Â»ç¶÷
³»¿ë
°³ÀÎÁ¤º¸Ã³¸®¹æħ
|
ȸ¿ø¾à°ü
|
°í°´Áö¿ø¼¾ÅÍ
|
Á¦ÈÞ ¹× ±¤°í¹®ÀÇ
|
´ÙÀÌ·ºÆ®°áÁ¦
¼³¸³ÀÏ : 2015³â 12¿ù 02ÀÏ l °³ÀÎÁ¤º¸Ã¥ÀÓÀÚ : À±º´È£
Á÷¾÷Á¤º¸Á¦°ø»ç¾÷½Å°í¹øÈ£ J150002023003
»ç¾÷ÀÚµî·Ï¹øÈ£ : 285-18-01963
| Åë½ÅÆǸž÷½Å°í : Á¦ 2023-ÀÎõ-0450È£
Copyright ¨Ï
Æĸ¶¸ÞµðÀâ
Co. Ltd. All rights reserved.